AKBA - Akebia kidney disease therapy undergoes FDA review again
2023-10-25 09:09:33 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia resubmits U.S. marketing application for kidney disease therapy
- Akebia gains as Australia clears kidney disease therapy
For further details see:
Akebia kidney disease therapy undergoes FDA review again